Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice

Stuart L. Goldberg, MD, Michael J. Mauro, MD, Jorge E. Cortes, MD, Scott Justin Keating, MSc, BSc, Hitesh Bhandari, Clara Chen, PhD BS, MS

Blood (2019) 134 (Supplement_1): 4151.

https://doi.org/10.1182/blood-2019-128290

Published: 2019

Journal Articles

Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Jorge E. Cortes, MD, Clara Chen, PhD BS, MS, Catherine Davis, PharmD, Stuart L. Goldberg, MD, Michael J. Mauro, MD

Blood (2019) 134 (Supplement_1): 2929.

https://doi.org/10.1182/blood-2019-127959

Published: 2019

Journal Articles

Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study

David Cella, PhD, Jan McKendrick, Harrison Davis, Ravi Vij, MBBS, Clara Chen, PhD BS, MS

Blood (2019) 134 (Supplement_1): 2190.

https://doi.org/10.1182/blood-2019-122668

Published: 2019

Journal Articles

Health-Related Quality-of-Life Outcomes in Patients with Classical Hodgkin Lymphoma: A Prospective, Observational Study in US Oncology Practices

Jakub Svoboda, MD, Philippe Armand, MD PhD, Fiona Taylor, Xiaowu Sun, Alejandro Moreno-Koehler, Srikanth Gajavelli, MD, Derek Peterson, Clara Chen, PhD BS, MS

Blood (2019) 134 (Supplement_1): 2192.

https://doi.org/10.1182/blood-2019-123980

Published: 2019

Journal Articles

Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study

Katja Weisel, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo

Blood (2019) 134 (Supplement_1): 3480.

https://doi.org/10.1182/blood-2019-122232

Published: 2019

Journal Articles

A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation

Clara Chen, PhD BS, MS, Philippe Armand, MD PhD, Basia Rogula, Karissa Johnston, Derek Peterson, Joseph M Connors, MD, Greta Lozano-Ortega, MSc

Blood (2019) 134 (Supplement_1): 4761.

https://doi.org/10.1182/blood-2019-122302

Published: 2019

Journal Articles

Cardiovascular Hospitalization in Patients Treated with Dasatinib or Nilotinib in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients in Routine Clinical Practice

Michael J. Mauro, MD, Clara Chen, PhD BS, MS, Jorge E. Cortes, MD, Carlo Gambacorti-Passerini, MD, Ginny P Sen, MPH, Srikanth Gajavelli, MD, Catherine Davis, Mauricette Michallet, MD PhD

Blood (2018) 132 (Supplement 1): 4258.

https://doi.org/10.1182/blood-2018-99-115903

Published: 2018

Journal Articles

Dosing Patterns of Dasatinib Use in Simplicity, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (pts) in Routine Clinical Practice

Jorge E. Cortes, MD, Clara Chen, PhD BS, MS, Michael J. Mauro, MD, Ginny P Sen, MPH, Srikanth Gajavelli, MD, Catherine Davis, PharmD, Stuart L. Goldberg, MD

Blood (2018) 132 (Supplement 1): 1730.

https://doi.org/10.1182/blood-2018-99-118119

Published: 2018

Journal Articles

Treatment Sequencing in Patients with Relapsed/Refractory Multiple Myeloma after Daratumumab Treatment: Real-World Findings from a Pooled Data Analysis of Preamble and the Mckesson Electronic Medical Record Database

Ravi Vij, MBBS, Clara Chen, PhD BS, MS, Christopher A. Yasenchak, MD, Catherine Davis, PharmD, David J. Kuter, MD

Blood (2018) 132 (Supplement 1): 3284.

https://doi.org/10.1182/blood-2018-99-112074

Published: 2018

Journal Articles

Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study

Gordon Cook, David Cella, PhD, Clara Chen, PhD BS, MS, Catherine Davis, PharmD, Brian GM Durie, MD, Hartmut Goldschmidt, MD, David J. Kuter, MD, Philippe Moreau, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 3285.

https://doi.org/10.1182/blood-2018-99-112081

Published: 2018

Journal Articles

Incremental Survival with Nivolumab Relative to Standard of Care in Classical Hodgkin Lymphoma: A Canadian Analysis

Greta Lozano-Ortega, MSc, Basia Rogula, Karissa Johnston, Julie Villeneuve, Andriy Moshyk, Heather O'Brien, Clara Chen, PhD BS, MS, Joseph M. Connors, MD

Blood (2018) 132 (Supplement 1): 5894.

https://doi.org/10.1182/blood-2018-99-111278

Published: 2018

Journal Articles

Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study

Katja Weisel, MD, Agne Paner, MD, Monika Engelhardt, MD, Fiona Taylor, Kim Cocks, Ashlee Espensen, Mihaela Popa-McKiver, PhD, Clara Chen, PhD BS, MS, Michele Cavo, MD

Blood (2018) 132 (Supplement 1): 2288.

https://doi.org/10.1182/blood-2018-99-112080

Published: 2018

Journal Articles

Healthcare Resource Utilization and Costs Associated with Different Treatment Modalities of Relapsed/Refractory Multiple Myeloma Patients in the US: Findings from Preamble

David J Kuter, MD DPhil, Clara Chen, PhD BS, MS, Sergey Popov, Catherine Davis, Ravi Vij, MD MBBS

Blood (2017) 130 (Supplement 1): 3157.

https://doi.org/10.1182/blood.V130.Suppl_1.3157.3157

Published: 2017

Journal Articles

Effect of Nivolumab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma after Autologous Transplantation: Results from the Multicohort Phase 2 Checkmate 205 Study

Andreas Engert, MD, Fiona Taylor, Bryan Bennett, Clara Chen, PhD BS, MS, Kim Cocks, Jeffrey McDonald, Erin Mann, Mariana Sacchi, David Cella, PhD

Blood (2017) 130 (Supplement 1): 3441.

https://doi.org/10.1182/blood.V130.Suppl_1.3441.3441

Published: 2017

Journal Articles

Side Effects and Supportive Care in Relapsed or Refractory Classical Hodgkin Lymphoma Patients Treated in Later Lines of Therapy: A Pilot Analysis Conducted in 4 Countries

Clara Chen, PhD BS, MS, Katherine Byrne, Pam Hallworth, Christopher A. Yasenchak, MD

Blood (2017) 130 (Supplement 1): 5653.

https://doi.org/10.1182/blood.V130.Suppl_1.5653.5653

Published: 2017

Journal Articles

Economic Burden in US Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin or Chemotherapy after Failure of Autologous Hematopoietic Cell Transplantation

Clara Chen, PhD BS, MS, Karissa Johnston, PhD, Shelagh Szabo, MSc, Joseph M Connors, MD, Christopher A. Yasenchak, MD

Blood (2017) 130 (Supplement 1): 4705.

https://doi.org/10.1182/blood.V130.Suppl_1.4705.4705

Published: 2017

Journal Articles

Cost Effectiveness of Nivolumab for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma (cHL) after Failure of Autologous Stem Cell Transplantation (ASCT) and Treatment with Brentuximab Vedotin (BV) Treatment in Australia

Marcus Tan, BPharm, Greta Lozano-Ortega, MSc, Shelagh Szabo, MSc, Karissa Johnston, PhD, Joseph M Connors, MD, Clara Chen, PhD BS, MS, Hansoo Kim

Blood (2017) 130 (Supplement 1): 2166.

https://doi.org/10.1182/blood.V130.Suppl_1.2166.2166

Published: 2017

Journal Articles

Treatment Patterns and Associated Outcomes in Patients with Relapsed or Refractory Multiple Myeloma in the US and Non-US Countries: Findings from Preamble

Ravi Vij, MD MBBS, Clara Chen, PhD BS, MS, Sergey Popov, Brian Durie, Gordon Cook, MD PhD, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Catherine Davis, Hartmut Goldschmidt, MD

Blood (2017) 130 (Supplement 1): 3123.

https://doi.org/10.1182/blood.V130.Suppl_1.3123.3123

Published: 2017

Journal Articles

Treatment Sequencing Patterns Observed in Patients Treated Initially with Lenalidomide/Dexamethasone Combination As Frontline Multiple Myeloma Therapy

Clara Chen, PhD BS, MS, Ravi Potluri, Hemanth Kanakamedala, Eros Papademetriou, Christopher A. Yasenchak, MD, Sandip Ranjan, Hitesh Bhandari, Jasdeep Mann, Catherine Davis

Blood (2017) 130 (Supplement 1): 3127.

https://doi.org/10.1182/blood.V130.Suppl_1.3127.3127

Published: 2017

Journal Articles

Duration of Treatment of Multiple Myeloma Regimens in Patients with Relapsed or Refractory Multiple Myeloma: Findings in US Clinical Practice Settings

Ravi Potluri, Hemanth Kanakamedala, Clara Chen, PhD BS, MS, Christopher A. Yasenchak, MD, Sandip Ranjan, Eros Papademetriou, Hitesh Bhandari, Jasdeep Mann, Catherine Davis

Blood (2017) 130 (Supplement 1): 1844.

https://doi.org/10.1182/blood.V130.Suppl_1.1844.1844

Published: 2017

NARROW

Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in Routine Clinical Practice

Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study

Health-Related Quality-of-Life Outcomes in Patients with Classical Hodgkin Lymphoma: A Prospective, Observational Study in US Oncology Practices

Impact of Elotuzumab Plus Pomalidomide and Dexamethasone on Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Enrolled in the ELOQUENT-3 Study

A Matching-Adjusted Indirect Comparison of Nivolumab Versus Brentuximab Vedotin for Relapsed/Refractory Classical Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation

Cardiovascular Hospitalization in Patients Treated with Dasatinib or Nilotinib in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients in Routine Clinical Practice

Dosing Patterns of Dasatinib Use in Simplicity, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (pts) in Routine Clinical Practice

Treatment Sequencing in Patients with Relapsed/Refractory Multiple Myeloma after Daratumumab Treatment: Real-World Findings from a Pooled Data Analysis of Preamble and the Mckesson Electronic Medical Record Database

Survival in Patients with Relapsed/Refractory Multiple Myeloma: Outcomes after 4 Years of the Ongoing Multinational Observational Preamble Study

Incremental Survival with Nivolumab Relative to Standard of Care in Classical Hodgkin Lymphoma: A Canadian Analysis

Quality-of-Life Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Treated with Elotuzumab Plus Pomalidomide and Dexamethasone: Results from the Phase 2 Randomized Eloquent-3 Study

Healthcare Resource Utilization and Costs Associated with Different Treatment Modalities of Relapsed/Refractory Multiple Myeloma Patients in the US: Findings from Preamble

Effect of Nivolumab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma after Autologous Transplantation: Results from the Multicohort Phase 2 Checkmate 205 Study

Side Effects and Supportive Care in Relapsed or Refractory Classical Hodgkin Lymphoma Patients Treated in Later Lines of Therapy: A Pilot Analysis Conducted in 4 Countries

Economic Burden in US Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin or Chemotherapy after Failure of Autologous Hematopoietic Cell Transplantation

Cost Effectiveness of Nivolumab for the Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma (cHL) after Failure of Autologous Stem Cell Transplantation (ASCT) and Treatment with Brentuximab Vedotin (BV) Treatment in Australia

Treatment Patterns and Associated Outcomes in Patients with Relapsed or Refractory Multiple Myeloma in the US and Non-US Countries: Findings from Preamble

Treatment Sequencing Patterns Observed in Patients Treated Initially with Lenalidomide/Dexamethasone Combination As Frontline Multiple Myeloma Therapy

Duration of Treatment of Multiple Myeloma Regimens in Patients with Relapsed or Refractory Multiple Myeloma: Findings in US Clinical Practice Settings

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only